Semantic confusion between “MD” and MDMA in Indian Addiction Psychiatry Practice

Dear Editor,

We wish to highlight a clinically significant but under-recognized terminological ambiguity increasingly encountered in Indian addiction psychiatry. The abbreviation “MD,” widely used in law enforcement communication, media reporting, and patient narratives, typically refers to synthetic cathinone mephedrone, also known as “meow-meow” (4-methylmethcathinone). However, clinicians unfamiliar with this regional slang may misinterpret “MD” as MDMA (3,4-methylenedioxymethamphetamine)—a pharmacologically and clinically distinct agent. In our day-to-day practice across Western India, this semantic overlap has repeatedly emerged as a barrier to accurate diagnostic assessment and treatment planning.

Recent enforcement data underline the prominence of mephedrone in India’s evolving synthetic drug landscape. According to the Narcotics Control Bureau’s Annual Report 2024, mephedrone seizures increased from 275 kg in 2020 to 3,559 kg in 2024, a more than thirteen-fold escalation.[1] The issue is further perpetuated in public discourse, as official documents and media outlets commonly use the shorthand “MD” when referring to mephedrone, seizures without specifying the underlying chemical identity, inadvertently reinforcing this confusion.[2] Unlike MDMA that is generally imported and consumed infrequently, mephedrone is often locally synthesized in small-scale setups, with regional seizure data supporting its domestic availability. As a result, patients presenting with stimulant use often report using “MD,” but closer exploration reveals patterns strongly suggestive of mephedrone consumption rather than MDMA exposure.

Our clinical encounters repeatedly demonstrate this ambiguity. Young male patients presenting with stimulant use frequently describe “MD” intake followed by short-acting, intensely stimulating effects lasting 2 to 4 hours, compulsive redosing, and fatigue or dysphoria afterward. In several cases, the substance has been consumed orally or mixed with smokeless tobacco (gutkha). These features are characteristic of mephedrone, a synthetic cathinone known for rapid onset, short duration, and high reinforcing potential.[3] In contrast, patients who genuinely use MDMA far fewer in number describe episodic, higher-cost “party drug” use, usually in tablet or capsule form, associated with empathogenic effects such as emotional warmth, sociability, heightened sensory perception, and occasional mild perceptual disturbances.[4] MDMA’s longer-lasting serotonergic profile and less compulsive pattern of use make its clinical presentation distinct from mephedrone’s stimulant-dominant clinical effect.

The pharmacological differences have important implications for diagnosis and management. Mephedrone functions as a potent serotonin–norepinephrine–dopamine reuptake inhibitor and releasing agent, producing pronounced euphoria, hyperstimulation, craving, and urges for rapid redosing, and its withdrawal phase frequently includes dysphoria, anxiety, irritability, craving, and cognitive slowing—symptoms that often require structured pharmacological and psychosocial management.[3] MDMA, by contrast, is primarily serotonergic, producing empathogenic and entactogenic effects, and withdrawal tends to involve irritability, sleep disturbances, anhedonia, and transient low mood.[4] Mephedrone has a rapid onset and shorter duration of action that promotes compulsive redosing behavior and exhibits greater abuse potential compared to MDMA.[5] Misclassification can therefore lead to inappropriate detoxification strategies or misaligned psychosocial interventions.

Nosologically distinctions further reinforce the need for precise identification. In ICD-11, mephedrone is categorized under Disorders due to use of other specified stimulants, including synthetic cathinones, whereas MDMA is classified under Disorders due to use of MDMA or related drugs, reflecting their differing stimulant and empathogenic properties. DSM-5 places mephedrone within Other or Unspecified Stimulant Use Disorder and MDMA under Other Hallucinogen Use Disorder, emphasizing the latter’s entactogenic–hallucinogenic profile.[6] These differences highlight the importance of clarifying substance identity during history-taking to avoid diagnostic ambiguity and inappropriate clinical pathways.

Based on repeated clinical encounters and the increasing prevalence of mephedrone across Indian states, we recommend that psychiatric training programs include structured exposure to regional and street-level substance terminology. Clinicians should routinely seek clarification when patients report “MD” use and, wherever feasible, incorporate mephedrone into toxicology screening panels or collaborate with forensic laboratories for chemical verification. Even when confirmatory testing is unavailable, awareness of mephedrone’s high prevalence, characteristic clinical profile, and common mislabeling as “MD” can substantially improve diagnostic accuracy and treatment outcomes.

As India confronts a rapidly shifting synthetic stimulant landscape, bridging the gap between colloquial drug terminology and clinical understanding is essential for evidence-based addiction care. Recognizing the semantic confusion surrounding “MD” represents a small but important step toward more accurate assessments and safer, more effective interventions.

Conflicts of interest

There are no conflicts of interest.

Funding Statement

Nil.